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Abstract Atrial and brain natriuretic peptides (ANP and BNP, 
respectively) are two cardiac natriuretic peptides (NPs) found in 
tetrapods from amphibians to mammals, whereas ANP and 
ventricular NP (VNP) have been identified in eel hearts. Because 
VNP has also been found in the rainbow trout ventricle, we 
attempted to isolate NP from trout cardiac atria in order to 
determine whether ANP and VNP are common cardiac NPs in 
teleosts. In the present experiments, we isolated VNP and a novel 
atrial NP consisting of 29 amino acid residues from the atria. 
This new trout NP exhibited similar sequence identity to 
mammalian ANP and BNP (50-60%). Its homology to eel 
ANP was low (52%) compared with high homology of trout and 
eel VNP (78%). Based on yield, the content of this new NP in 
trout atria may be even smaller than that of VNP. The new trout 
atrial NP exhibited low relaxant activity in the chick rectum 
(only 1/10 of that of trout VNP), and extremely low vasorelaxant 
activity in the rat aortic strip (only 11400 of that of human ANP). 
However, the new trout NP was equipotent with trout VNP and 
human ANP in relaxing trout epibranchial artery. Based on the 
sequence similarity with other NPs and on atrial content, the new 
NP isolated from trout atria cannot yet be assigned to a known 
member of the NP family. 
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osts, respectively, or if they are on the same line of molecular 
evolution in the NP family. Since both the amino acid and 
nucleotide sequences of VNP are more similar to ANP than to 
BNP [6], VNP may have diverged from CNP before ANP. 
Alternatively, both VNP and BNP may have branched from 
ANP early in the course of NP evolution. 
VNP has previously been isolated from the cardiac ventricle 
of rainbow trout [7]; however, several previous attempts to 
isolate ANP from atria, including efforts from our laboratory, 
have not been successful. This may be due to the low immu- 
noreactivity to antisera against mammal ian ANP and/or low 
biological activity in the assay system. Because ANP is a 
rather conservative molecule in the NP family, it is possible 
that a new type of NP could be present in trout atria. In the 
present study, we isolated a new NP from trout atria which is 
equally homologous to ANP and to BNP. This trout NP has 
very low biological activity in the chick rectum and rat aorta 
compared with trout VNP, but exhibited similar vasorelaxant 
activity in trout arteries. 
2. Materials and methods 
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I. Introduction 
Atrial, brain, and C-type natriuretic peptides (ANP, BNP 
and CNP) form a peptide family which displays a spectrum of 
actions involved in volume and pressure homeostasis [1]. ANP 
and BNP are true hormones ecreted by the heart, while CNP 
is a paracrine factor in the brain and other peripheral tissues 
[2]. All three peptides (ANP, BNP and CNP) appear to be 
present in tetrapods [3]. In the eel, however, ANP and ven- 
tricular NP  (VNP) are the only known cardiac hormones, 
CNP may originate in the brain, and all three can be found 
in the circulation [4]. CNP is the only hormone in the heart 
and brain of the more primitive carti laginous fish and it is 
believed to be an ancestral molecule of the NP  family [5]. 
In view of the evolution of NP  molecules, it is of interest o 
determine if BNP and VNP are unique to tetrapods and tele- 
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2.1. Isolation qf NP jrom atria 
Cardiac atria were isolated from 250400 g rainbow trout, Onco- 
rhvnchus mykiss, of both sexes just after decapitation, and frozen 
immediately on dry ice. The frozen tissues were shipped on dry ice 
from Indiana t ~niversity o University of Tokyo and stored at -80°C 
until use. 
Frozen atria (300 g) were pulverized and heated in a boiling water 
bath with 5 volumes of distilled water for 10 min. After cooling, acetic 
acid (AcOH) was added to a final concentration f 1 M. The mixture 
was homogenized with a Polytron (Kinematika, Switzerland) lbr 3 min 
at maximum speed. The homogenate was centrifuged at 17 700 × g for 
30 min at 4°C. The supernatant was treated with 66.7% and 98.5% 
(final) of cold acetone to remove high-molecular protein and lipids, 
respectively. The sample was applied to a column of Sephadex G-25 
fine (5 × 80 cm. Pharmacia, Sweden) for desalting. The NP activity in 
each fraction was assayed by relaxant activity in the chick rectum as 
described below. Bioactive fractions were subjected to cation-exchange 
chromatography in an SP-Sephadex C-25 column (100 ml, Pharma- 
cia), and adsorbed materials were eluted successively with 400 ml each 
of 1 M AcOH, 2 M pyridine, and 2 M pyridine-AcOH, pH 5.0, Since 
bioactivity was evident in the pyridine-AcOH fraction, it was subjected 
to cation-exchange high performance liquid chromatography (HPLC) 
in an SP-2SW column (4.6×250 ram, Tosoh, Japan). Each bioactive 
fraction was then subjected to gel-permeation HPLC in a column of 
Superdex Peptide HR 10/30 (10 x 300 mm, Pharmacia). Each bioactive 
fraction was further purified by sequential reverse-phase HPLC, first 
on an ODS-120T (4.6×250 ram, Tosoh) column and then on a 
219TP54 diphenyl (4.6 × 250 mm, Vydac, USA) column, Elution con- 
ditions for HPLC are described in the legend of each figure. The 
column effluents were monitored by absorbance at220, 230 or 280 nm. 
0014-5793/97l$17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
PII S00 1 4-5 793(  97)01 050-8  
378 
2.2. Mass pectrometry and sequence analysis 
Mass spectrometry was carried out with 1/100 of the purified pep- 
tide in a KOMPACT MALDI III mass spectrometer (Shimadzu, Ja- 
pan). Amino acid sequence was determined with half of the purified 
peptide in an automated gas-phase protein sequencer (Model 476A, 
Applied Biosystems Inc., USA). The remaining peptide was used for 
confirmation of identity with the synthetic peptide (see below). 
2.3. C-terminal analysis" 
Since the molecular mass calculated from the sequenced ata did 
not coincide with the data of mass spectrometry, C-terminal analysis 
of the purified peptide was performed by carboxypeptidase digestion 
coupled with mass spectrometry [8]. The accuracy of this method 
resolves one mass difference, thereby enabling differentiation between 
an amidated and non-amidated C-terminus. The peptide was digested 
with carboxypeptidase Y (Wako Pure Chemicals, Japan) at 2 pmol/5 
mU in 100 mM N-ethylmorpholine (Wako), pH 6.0, at 22°C for 15 
min, and analyzed in a mass spectrometer (Voyager Elite, Applied 
Biosystems Inc.). An amino acid residue at the C-terminus was deter- 
mined by the difference of molecular mass between undigested and 
digested peptide. Since a non-amidated Ser residue was detected at the 
C-terminus, it was synthesized in the protein synthesizer (Model 
430A, Applied Biosystems Inc.). The remaining purified peptide was 
finally co-chromatographed with synthetic peptide to confirm the 
identity in ODS-120T and 219TP54 diphenyl columns at a gradient 
of 10 30% CH3CN concentration for 40 min. 
2.4. Relative potency ofnew NP 
Biological activity of the new atrial NP relative to trout VNP and 
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human ANP was examined in three in vitro systems: relaxant activity 
in the chick rectum [9], vasorelaxant activity in the rat thoracic aorta 
[10], and vasorelaxant activity in the trout epibranchial artery [ll]. 
Isotonic displacement was measured for the chick rectum and rat 
vessel, while isometric tension was measured for the trout vessel. 
The synthetic new trout NP, trout VNP, and human ANP (Peptide 
Institute Inc.) were dissolved in isotonic (0.9%) NaCI solution, and 
administered in random order of drugs and doses. The relative po- 
tency of the trout NP was calculated by 2× 3 point analysis after 
parallelism of two dose-response curves was confirmed [12]. The dif- 
ference of the effects of two drugs was statistically examined by AN- 
OVA. The ratio was expressed with 95% confidence interval. Other 
data were expressed as means _+ S.E.M. 
3. Results 
3.1. Isolation and sequence determination 
After desalting with Sephadex G-25 column, SP-Sephadex 
C-25 chromatography yielded 40 nmol of rectum relaxant 
activity equivalent to eel ANP in the pyridine-AcOH fraction. 
After cation-exchange HPLC of the fraction, the bioactivity 
was scattered over many fractions (Fig. la). The bioactive 
fractions were divided into three groups according to the 
peaks, and each group with same relaxant activity (7 nmol) 
was pooled and further purified by gel-permeation HPLC and 
several steps of reverse-phase HPLC. A new peptide was iso- 
a . . . . . . .  lOO 
/// 1 ~E_ 
~=o.5 / | Z e, 
.," ~o ~ ~ 1.o 
..." "6 3 
,IT, W Xl  "° 
o o~ o IIIIIII Jo~ 
t2  
lb 20 3'0 ~ 0 10 20 30 
Fract ion  number  Fract ion  number 
E 
c 
~ 0 .5  
3 
E 
o 
< 
c d 
E 
t 
60 = 
*~ ~ o.ol 
3s = 
E 
< o 
0 20 40 60 
Time (rain) 
25 o~ 
10 < 
t , 
0 1() 2'0 30 
Time (rain) 
Fig. 1. a: Cation-exchange HPLC on an SP-2SW column. Sample: fraction eluted with 2 M pyridine-AcOH from SP-Sephadex C-25. Elution: 
from solvent A (10 mM AcONH4 in 10%o CH3CN) to 50% solvent B (1 M AcONH4 in 10% CH3CN ) for 60 rain, and to 100% solvent B for 
20 rain. Flow rate: 1 ml/min. Fraction size: 2.5 ml/tube. Black columns represent relaxant activities in the chick rectum expressed as equiva- 
lents of eel ANP. b: Gel-permeation HPLC on a Superdex Peptide column. Sample: peak l in (a). Flow rate: 0.25 ml/min. Fraction size: 
0.625 ml/tube. Eluant: 30% CH3CN in 0.1% trifluoroacetic acid (TFA). c: Reverse-phase HPLC on an ODS-120T column. Sample: peak 1 in 
(b). Elution: 10% to 60% CH3CN in 0.1% TFA for 60 min. Flow rate: 1 ml/min. Fraction was collected by each peak. d: Reverse-phase 
HPLC on a 219TP54 diphenyl column. Sample: peak marked in (c). Elution: 10% to 25% CH:~CN in 0.1% TFA for 30 min. Other conditions 
were identical to (c). 
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lated from peak 1 (see below), whereas trout VNP-(I 36) was 
isolated from peak 2 and trout VNP-(1 32) was isolated from 
peak 3 (data not shown). The final recovery of VNP-(1-36) 
and VNP-(1 32) was 470 and 350 pmol, respectively, equiv- 
alent to eel ANP as determined by absorbance at 220 nm. 
After gel-permeation HPLC of peak 1, two fractions exhib- 
ited high rectum relaxant activity (Fig. lb). The fraction dis- 
playing the highest activity was subjected to reverse-phase 
HPLC with an ODS column, but the assay using 1/5 of the 
fraction collected by each peak reflection did not show any 
significant activity (Fig. lc). However, a possible fraction 
marked by an arrow was further purified by another re- 
verse-phase HPLC with a diphenyl column, and the material 
in the major peak reflection was analyzed by mass spectrom- 
etry (Fig. td). Mass analysis of" the final product revealed a
single peak with a molecular mass of 2972 (data not shown). 
Sequence analysis of half of the purified peptide resulted in 
Ser-Lys-Ala-Val-Ser-Gly-Cys-Phe-Gly-Ala-Arg-Met-Asp-Arg- 
Ile-Gly-Thr-Ser-Ser-Gly-Leu-Gly-Cys-Ser-Pro-Lys-Arg-Arg. 
The fraction showing the second highest activity after gel-per- 
meation HPLC was also purified as above, and the same 
peptide was recovered (data not shown). The final yield 
from both fractions was 400 pmol equivalent to eel ANP by 
absorbance at 220 nm, 
The molecular mass calculated from the above sequence, 
however, was ca. 87 smaller than the value measured by 
mass spectrometry. Mass spectrometry after digestion of the 
peptide with carboxypeptidase Y displayed two distinct peaks, 
one at 2972.48 (major) and a second at 2885.38 (minor) (data 
not shown). Since the difference (87.1) exactly coincided with 
a Ser residue, we determined that a non-amidated Ser residue 
is attached to the C-terminal Arg residue of the deduced se- 
quence (Fig. 2). The theoretical molecular mass calculated 
from this sequence was 2972.4. The sequence was finally con- 
firmed by co-chromatography of the purified peptide with 
synthetic peptide in two different HPLC systems. 
3.2. Bioh~gical activiO 
The trout NP induced a dose-dependent relaxation in the 
precontracted chick rectum~ hut it was significantly ess potent 
than either trout VNP or human ANP (Fig. 3a). The potency 
ratio for trout NP was 0.09 (0.08-0.10) compared to trout 
VNP and 0.25 (0.18 0.34) compared to human ANP. Trout 
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Fig. 2. Comparison of amino acid sequence of new trout atrial NP 
with other natriuretic peptides sequenced to dat . Amino acid resi- 
dues identical to trout atrial NP are reve sed. 
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Fig. 3. a: Relaxant activity in thechick rectum (n=8). b: Vasore- 
laxant activity in the rat aortic strip (n = 6). c: Vasorelaxant activity 
in the trout efferent epibranchial artery (n=8)of trout atrial NP 
(O), trout VNP (I) and human ANP (4?). Values are means 
+ S.E.M. 
NP was even less efficacious in the precontracted rat thoracic 
aorta (Fig. 3b) where the potency ratio was only 0.0027 
(0.0019-0.0033) compared to human ANP. However, trout 
NP was equipotent with both trout VNP and human ANP 
in its ability to relax the trout efferent epibranchial artery 
(Fig. 3c). Neither homologous trout peptide was more potent 
than human peptide in the trout artery. 
4. Discussion 
Rainbow trout are the most frequently used fish species for 
basic fish research and aquaculture [13]. They are particularly 
good research models for osmoregulatory studies because of 
their tolerance to a wide range of environmental s linities [14]. 
Thus a detailed examination of osmoregulatory hormones, 
such as NPs, in these fish has both general and practical value. 
Surprisingly, however, only VNP has been isolated from rain- 
bow trout [7] or from a related species, the chum salmon, 
Oncorhynchus keta (A. Fukuzawa and Y. Takei, unpublished 
observation). Even though these and other studies attempted 
to identify a salmonid ANP using the classical chick rectum 
bioassay, they were not successful. In addition, a number of 
attempts have been made to isolate ANP from trout or sal- 
mon atria using immunoreactivity to mammalian ANP as an 
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assay system; however, to ur knowledge these have likewise 
been unsuccessful. This suggests that either there is quantita- 
tively little trout atrial NP or it is functionally and/or struc- 
turally quite different from other ANP molecules. In the 
present study, a new NP was isolated from trout atria even 
though its biological activity, as determined with standard 
bioassay techniques, was extremely low. Our success may be 
partially due to our use of gel-permeation HPLC which per- 
mitted us to decrease the frequency of subsequent reverse- 
phase HPLC. In fact, isolation of VNP from atria in this 
study was also due to this improved technique. 
The new trout atrial NP is equally similar to both ANP and 
BNP and it is thus far impossible to determine whether it is 
ANP or BNP. The ANP content in atria was several orders of 
magnitude larger than that of BNP or VNP in any mamma- 
lian and teleostean species thus far examined [15,16]. How- 
ever, atrial content of the new NP appears to be smaller than 
that of VNP judging from the recovery of each peptide from 
trout atria. The sequence of the C-terminal end of the present 
NP consists of 6 amino acid residues, which has more simi- 
larity to BNP (6 residues) than to ANP (5 residues), but there 
are some exceptions [3] (Fig. 2). If the new NP belongs to the 
ANP group, it is evident hat ANP is structurally more var- 
iable than VNP; sequence identity of ANP between trout and 
eel (52%) is much less than that of VNP (78%) [7]. In mam- 
mals, ANP is more highly conserved than BNP [4]. If the new 
NP is BNP, on the other hand, it will provide a new insight 
into the molecular evolution of the NP family. In order to 
reach a conclusive decision, it is necessary to isolate the pep- 
tide's cDNA and examine whether it possesses even repeti- 
tions of the ATTTA sequence in the 3' noncoding region 
because this characteristic is common to all BNP cDNAs 
thus far cloned [17]. 
It is perhaps urprising that human ANP was as effective as 
homologous trout NPs for the vasorelaxant activity in the 
trout artery. In the eel, for instance, the vasodepressor activity 
of eel NPs are 100-fold more potent han that of human ANP, 
and the opposite is true in the rat [18]. Since homology be- 
tween human ANP and trout NPs is low, it is possible that 
these peptides may not share the same receptors. Therefore, 
another NP that is more closely related to human ANP and 
shares a receptor with human ANP might be present in the 
trout. In mammals, two guanylyl cyclase (GC) coupled recep- 
tors responsible for biological actions of NP peptides are 
identified: GC-A for ANP and, to a lesser extent, BNP and 
GC-B for CNP [19]. In teleost fishes, GC-B has been cloned in 
the eel [20]. Eel GC-B expressed in COS cells exhibited a 
potency order for cGMP production of CNP > VNP > ANP. 
The presence of GC-A type receptor is also demonstrated in
the kidney and intestine of the eel [21], and eel GC-A cDNA 
has recently been cloned (M. Kashiwagi and S. Hirose, per- 
sonal communication). Since VNP has a unique structure with 
a long C-terminal sequence, it is possible that new receptors 
specific to VNP are also present in teleost fishes. In this way, 
studies on the fish NP system will give us a new insight into 
the evolution of this system. 
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